West Pharmaceutical Services (WST) Capital Expenditures (2009 - 2026)

West Pharmaceutical Services has disclosed Capital Expenditures across 18 years of filings, most recently posting $26.1 million for Q1 2026.

• Capital Expenditures for Q1 2026 came in at $26.1 million, down 63.39% year-over-year; the trailing twelve-month figure through Mar 2026 was $240.7 million (up 206.23% YoY), and the FY2025 annual result was $285.9 million, up 439.43% from the prior year.
• Capital Expenditures came in at $26.1 million for Q1 2026 at West Pharmaceutical Services, down from $76.1 million in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $230.5 million in Q3 2024 to a low of -$219.1 million in Q4 2024.
• The 5-year median for Capital Expenditures is $66.1 million (2022), against an average of $44.7 million.
• Across the five-year window, Capital Expenditures plunged 301.56% in 2024 and jumped 1934.15% in 2025, its largest moves.
• West Pharmaceutical Services' Capital Expenditures stood at -$156.5 million in 2022, then surged by 169.46% to $108.7 million in 2023, then sank by 301.56% to -$219.1 million in 2024, then soared by 134.73% to $76.1 million in 2025, then sank by 65.7% to $26.1 million in 2026.
• The last three Capital Expenditures figures came in at $26.1 million (Q1 2026), $76.1 million (Q4 2025), and $63.3 million (Q3 2025), per Business Quant data.